| Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 136, 2023 | 12 | 2023 |
| A severe case of levothyroxine intoxication successfully treated in intensive care unit Y Savran, T Mengi, M Keskinkilic Journal of Acute Disease 7 (4), 175-177, 2018 | 10 | 2018 |
| Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study HÇ Yıldırım, E Mutlu, E Chalabiyev, M Özen, M Keskinkılıç, S Ön, A Çelebi, ... The Breast 66, 85-88, 2022 | 8 | 2022 |
| The role of immune checkpoint inhibition in triple negative breast cancer K Tarekegn, M Keskinkilic, TJ Kristoff, ST Evans, K Kalinsky Expert Review of Anticancer Therapy 23 (10), 1095-1106, 2023 | 6 | 2023 |
| The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma HI Ellez, M Keskinkilic, HS Semiz, ME Arayici, E Kısa, I Oztop Journal of Clinical Medicine 12 (17), 5434, 2023 | 6 | 2023 |
| The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification?(Turkish Oncology … M Hizal, B Bilgin, N Paksoy, MM Atcı, S Kahraman, S Kılıçkap, DC Güven, ... Journal of Cancer Research and Clinical Oncology 149 (8), 4141-4148, 2023 | 5 | 2023 |
| Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer S Kahraman, E Erul, M Seyyar, O Gumusay, E Bayram, BC Demirel, ... Future Oncology 19 (10), 727-736, 2023 | 5 | 2023 |
| The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and … EC Yildirim, E Atag, E Coban, OU Unal, A Celebi, M Keser, M Uzun, ... The Breast 70, 56-62, 2023 | 4 | 2023 |
| CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma HS Semiz, Ü Küçük, E Kısa, M Keskinkılıç, DE Süyün, ME Arayıcı, E Atağ, ... The Prostate 82 (16), 1564-1571, 2022 | 4 | 2022 |
| The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer … HÇ Yıldırım, Y Kutlu, E Mutlu, MB Aykan, M Korkmaz, S Yalçın, T Şakalar, ... International Journal of Clinical Oncology 29 (3), 258-265, 2024 | 2 | 2024 |
| 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience M Keskinkılıç, HS Semiz, T Yavuzsen, A Karaoglu Annals of Oncology 33, S216, 2022 | 2 | 2022 |
| Approach to the Treatment of Metastatic Castration-Sensitive Prostate Carcinoma: A Single Center Experience HS Semiz, M Keskinkılıç, HI Ellez, ME Arayıcı, A Karaoglu Journal of Basic and Clinical Health Sciences 6 (1), 296-304, 2022 | 2 | 2022 |
| Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on … HC Yildirim, C Kapar, B Koksal, M Seyyar, PC Sanci, M Guliyev, P Perkin, ... Journal of Chemotherapy, 1-7, 2024 | 1 | 2024 |
| The comparison of functional status and health-related parameters in ovarian cancer survivors with healthy controls SC Gultekin, AB Cakir, ZG Guc, FR Ozalp, M Keskinkilic, T Yavuzsen, ... Supportive Care in Cancer 32 (2), 119, 2024 | 1 | 2024 |
| Triple Negative Breast Cancers–an obsolete entity? M Keskinkılıc, Y Gökmen-Polar, SS Badve Clinical Breast Cancer, 2023 | 1 | 2023 |
| The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index M Keskinkilic, HS Semiz, G Polat, ME Arayici, T Yavuzsen, I Oztop Future Oncology 19 (7), 517-529, 2023 | 1 | 2023 |
| Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study M Hizal, B Bilgin, N Paksoy, S Kılıçkap, MM Atcı, S Kahraman, ... Future Oncology 18 (23), 2573-2582, 2022 | 1 | 2022 |
| High Creatinine Level Secondary to Use of CDK 4/6 Inhibitor Treatment (Palbociclib and Ribociclib)+ Endocrine Therapy (ET) M Keskinkilic, HS Semiz, T Yavuzsen, A Karaoglu Journal of the College of Physicians and Surgeons--Pakistan: JCPSP 34 (7 …, 2024 | | 2024 |
| Natural products to enhance anti-tumor effects of trastuzumab and paclitaxel on the SKBR3, which is human breast cancer cell line. M Keskinkilic, FM Altinay, A Pavlopoulou, T Yavuzsen, M Gumustekin, ... Journal of Clinical Oncology 42 (16_suppl), e13051-e13051, 2024 | | 2024 |
| The prognostic value of immune-nutritional status in metastatic colorectal cancer: Prognostic Nutritional Index (PNI) M Keskinkilic, HS Semiz, E Ataca, T Yavuzsen Supportive Care in Cancer 32 (6), 1-10, 2024 | | 2024 |
